JOHNSON
CITY, Tenn. and NASHVILLE,
Tenn., May 6, 2021
/PRNewswire/ -- LabConnect, Inc. and Cryoport,
Inc. (NASDAQ: CYRX) today announced a partnership to provide
comprehensive logistics support for an upcoming Phase I/II
clinical trial sponsored by Triumvira Immunologics
Inc., a privately held biopharmaceutical company developing a
novel platform for engineering T cells to attack cancers. The
study intends to investigate the safety and efficacy of autologous
TAC-T Cells (TAC01-HER2) targeting HER2 in relapsed or refractory
solid tumors.
The partnership will integrate Cryoport's Cryoportal®
Logistics Management Platform and LabConnect's SampleGISTICS™
platform to provide Triumvira with the highest possible
available level of tracking and proactive management for their
samples, source materials, and therapeutic product. Each step from
scheduling, sample collection, confirming courier
pickups/deliveries, and monitoring transport will be monitored by
LabConnect and Cryoport project management.
LabConnect, the leader in innovative central laboratory services
for cell and gene therapy clinical trials, will utilize its virtual
accessioning system and proprietary tracking platform
SampleGISTICS™ to capture real time data from the time of sample
and source material collection. In addition, LabConnect will
provide advanced analytical support, customized collection
supplies, project management, and data management support.
"We are excited to be collaborating with Cryoport as they share
our commitment to cell and gene therapy trial service innovation,"
said Tom Sellig, CEO of
LabConnect. "The integrated solution will provide Triumvira
with a seamless level of support to ensure successful execution of
their clinical program."
Cryoport, a global leader in temperature-controlled supply chain
solutions for the life sciences industry, will provide its advanced
logistics solutions designed for near real-time tracking and
monitoring of clinical and commercial advanced therapy products.
These unique temperature-controlled logistics solutions are
composed of a host of advanced technologies including Cryoport
Express® Shippers, which include its C3TM
line of CRT (controlled room temperature) shippers, its SmartPak
II® Condition Monitoring System and its
Cryoportal® Logistics Management Platform.
"Collaborations such as this one with LabConnect expand our
ecosystem of temperature-controlled supply chain solutions for the
regenerative medicine market, enabling us to better serve the life
sciences on a broader basis, which enables us to bring on new
clients," said Jerrell Shelton, CEO
of Cryoport. "We are committed to meeting the increasingly complex
needs of cell and gene therapy developers with our highly
differentiated and specialized solutions to support the advancement
of regenerative medicines and the continuous evolution of life
sciences."
About LabConnect
LabConnect is the preeminent provider of central laboratory
support services for analytically and logistically complex studies
such as cell and gene therapies, immuno-oncology, and rare &
orphan diseases. LabConnect offers unique and innovative services
that have been specifically designed to meet the exacting demands
of today's clinical trials. Its worldwide scope of services
includes routine and specialized testing, real-time sample
tracking, data integration, biorepository, sample processing and
specialized functional outsourcing. Leading the evolution in
central laboratory services since 2002, LabConnect's services are
customized to reduce risk in complex clinical studies. Get
connected at www.labconnect.com or via email at
info@labconnect.com.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) is redefining
temperature-controlled supply chain support for the life sciences
industry by continually broadening its platform of solutions and
services, serving the Biopharma, Reproductive Medicine, and Animal
Health markets. Through its family of companies, Cryoport Systems,
MVE Biological Solutions, CRYOPDP and CRYOGENE, Cryoport provides
strategic solutions that support the growing needs of these
markets.
Cryoport's mission is to support life and health on earth
through its advanced technologies, global supply chain network and
dedicated scientists, technicians and supporting teams of
professionals. Cryoport serves clients in life sciences research,
clinical trials, and product commercialization. We support the
creation of life, the sustaining of life and life-saving advanced
cell and gene therapies in over 100 countries around the world. For
more information, visit www.cryoport.com or follow @cryoport on
Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely
historical, including statements regarding the Company's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, plans, strategy, acquisitions,
including CRYOPDP and MVE Biological Solutions, financial results
and financial condition. It is important to note that the
Company's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to, risks
and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors, including the risk factors discussed in
the Company's Securities and Exchange Commission ("SEC") reports
including, but not limited to, the Company's Annual Report on Form
10-K for the three and twelve months ended December 31, 2020 and any subsequent filings with
the SEC. The forward-looking statements contained in this press
release speak only as of the date hereof and the Company cautions
investors not to place undue reliance on these forward-looking
statements. Except as required by law, the Company disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/labconnect-and-cryoport-partner-to-provide-support-for-innovative-triumvira-cell-and-gene-therapy-clinical-trial-301285468.html
SOURCE Cryoport, Inc.